Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
复制标题
DOI：
10.1086/315009
复制
发表时间：
1999-10-01
影响因子：
6.4
通讯作者：
Klugman, KP
中科院分区：
文献类型：
--
作者：
Mbelle, N;Heubner, RE;Klugman, KP
在南非索韦托的500名婴儿中进行了一项双盲、随机、安慰剂对照试验，检查了6、10和14周龄时接种的非价肺炎球菌疫苗的安全性、免疫原性和对携带的影响。未记录严重的局部或全身副作用。在第三次给药后4周观察到对所有肺炎球菌血清型的显著抗体应答。接受肺炎球菌结合物治疗的儿童的流感嗜血杆菌B型多聚核糖基核糖醇磷酸盐（几何平均滴度，11.62 μ g/mL）和白喉（1.39 IU/mL）抗体显著高于安慰剂治疗的儿童（分别为4.58 μ g/mL和0.98 IU/mL）。与对照组相比，接种疫苗9个月后，接种者鼻咽部疫苗血清型携带率下降（18%对36%），而非疫苗血清型携带率增加（36%对25%），青霉素耐药肺炎球菌携带率（21%对41%）和复方新诺明耐药肺炎球菌携带率（23%对35%）在接种后9个月显著降低。
The safety, immunogenicity, and impact on carriage of a nonvalent pneumococcal vaccine given at ages 6, 10, and 14 weeks were examined in a double-blind, randomized, placebo-controlled trial in 500 infants in Soweto, South Africa. No serious local or systemic side effects were recorded. Significant antibody responses to all pneumococcal serotypes were observed 4 weeks after the third dose. Haemophilus influenzae type b polyribosylribitol phosphate (geometric mean titer, 11.62 mu g/mL) and diphtheria (1.39 IU/mL) antibodies were significantly higher in children receiving pneumococcal conjugate, compared with placebo recipients (4.58 mu g/mL and 0.98 IU/mL, respectively). Nasopharyngeal carriage of vaccine serotypes decreased in vaccinees at age 9 months (18% vs. 36%), whereas carriage of nonvaccine serotypes increased (36% vs. 25%), Carriage of penicillin-resistant pneumococci (21% vs, 41%) and cotrimoxazole-resistant pneumococci (23% vs. 35%) were significantly reduced 9 months after vaccination, compared with controls.